Caredx Stock News

EDEN PRAIRIE, Minn., March 16, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO ), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients'' lives, announced its participation in CareDx''s Xenotransplantation Innovation Day, a virtual event that will feature a leading panel of transplant experts who will share the latest advancements in the field. CareDx''s Xenotransplantation Innovation Day will be held on March 22, 2022, from 11:00 am to 12:00 pm Central Time / 12:00 pm to 1:00 pm Eastern Time. The presentations and panel discussions will be held in a virtual format to enable a wide audience to learn from these experts. The symposium will include an update on the world''s first living pig-to-human heart transplant from the University of Maryland School of Medicine, an update on the world''s first transplant of a gene-edited pig kidney from NYU Langone Health, and a development update regarding human-compatible organs from eGenesis and an update on bioengineered livers and kidneys for transplant from Miromatrix.

LITHIA, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- The nonprofit Transplant Recipients International Organization (TRIO) today praised a federal jury''s $44.9 million verdict award to CareDx, Inc., finding that a transplant test provider and its senior executives intentionally and recklessly made misleading statements about the veracity of its test for kidney transplant effectiveness. "The verdict handed down on Monday ultimately benefits patients whose lives depend on rigorous, reliable science and clinical excellence," said TRIO President James … Full story available on Benzinga.com

Genetic testing company Natera Inc owes rival CareDx Inc $44.9 million for making false claims about the effectiveness of Natera''s Prospera test for assessing the risk that a person''s body will reject a kidney transplant, a Delaware jury said.

CareDx (CDNA) announced that the Company won its false advertising case against Natera (NTRA) as a jury found that Natera and its senior executives intentionally and recklessly misled…

Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds CareDx Advertising of AlloSure to be Accurate and Truthful Jury Finds Natera Falsely Advertised its Prospera K

NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agrify Corporation (NASDAQ: AGFY), Cronos Group, Inc. (NASDAQ: CRON), Everbridge, Inc. (NASDAQ: EVBG), and CareDx, Inc. (NASDAQ: CDNA). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

CareDx (CDNA) said its French strategic partner Cibiltech began the CIBIL clinical trial to evaluate the performance of iBox artificial intelligence ((AI)) as a prognostic measure of…

CareDx (CDNA) delivered earnings and revenue surprises of -250% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CareDx press release (NASDAQ:CDNA): Q4 Non-GAAP EPS of -$0.03 misses by $0.06.Revenue of $79.22M (+35.1% Y/Y) beats by $1.12M.

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically di

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the fourth quarter and full year ended December 31, 2021.

CareDx, Inc (CDNA) CEO Reg Seeto on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced that its non-invasive organ transplant surveillance solutions are being used to help monitor post-operative graft health in the world''s first successful heart xenotransplantation. A genetically modified pig heart was successfully transplanted into a patient at the University of Maryland Medical Center on January 7, 2022. Surgeons from the University of Maryland School of Medicine (UMSOM) are using adapted versions of two complementary, non-invasive CareDx surveillance solutions, experimentally, to provide a comprehensive, multimodal assessment of organ graft health. Gene expression profiling is being used to assess immune quiescence and donor-derived cell-free DNA (dd-cfDNA) to detect graft injury. "As an innovator in organ transplant surveillance, CareDx is proud to be working with UMSOM on this landmark case which represents a groundbreaking moment in the history of transplantation," said Reg Seeto, CEO and President of CareDx. "It''s incredibly rewarding to apply our years of experience and dedication to the transplant community by offering the world''s first biomarker surveillance solution for xenotransplantation.